Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7540660 | 0.73 | ALDH1A1 (0.48) | ALDH1A1SLC27A1RAB9A | |
| SCHEMBL7542661 | 0.69 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL7545430 | 0.68 | ALOX5 (0.32) | SLC27A1 | |
| SCHEMBL11359838 | 0.64 | ALOX15 (0.39) | ALDH1A1SLC27A1RAB9A | |
| SCHEMBL7540486 | 0.63 | SLC27A1 (0.33) | ALDH1A1SLC27A1 | |
| SCHEMBL1842323 | 0.63 | NPC1 (0.52) | ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL1844041 | 0.62 | NPC1 (0.51) | ALDH1A1RAB9A | |
| SCHEMBL7539138 | 0.60 | SMN1; SMN2 (0.48) | ALDH1A1RAB9A | |
| SCHEMBL7535208 | 0.59 | MAPK1 (0.50) | RAB9A | |
| SCHEMBL7534511 | 0.59 | ALDH1A1 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |